A Case of Steatocystoma Multiplex in a Psoriatic Patient During Treatment with Anti-IL-12/23

    January 2020 in “ Skin Appendage Disorders
    Claudio Marasca, Matteo Megna, Marianna Donnarumma, Giuseppina Fontanella, Eleonora Cinelli, Gabriella Fabbrocini
    TLDR Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.
    The document reported a case of steatocystoma multiplex (SM) in a psoriatic patient undergoing treatment with ustekinumab, an IL-12/IL-23 inhibitor. SM is characterized by multiple asymptomatic cutaneous cysts and is linked to a mutation in the keratin 17 gene (KRT17). The authors hypothesized that ustekinumab might have revealed a genetic predisposition to SM by reducing the expression of interferon-γ and IL-17/IL-22, thereby affecting the K17 pathway.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 87 results